CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel cancer immunotherapy using engineered B cells. By utilizing advanced gene editing techniques, the project aims to enhance the immune response against tumors, enabling targeted delivery of anti-tumor antibodies and other immune effectors to improve treatment outcomes.
B cells have an important role in the immune response against cancer.
Tumor specific B cells in tertiary lymphoid structures and anti-tumor antibodies in the plasma are associated with a favorable prognosis and with an improved response to checkpoint inhibition in different sarcomas and carcinomas.
Antigen specific B cells home to tumors and prolong survival in mice, while B cell based vaccines allow durable anti-tumor activity in cervical cancer patients.
We have recently demonstrated both ex v…
TEL AVIV UNIVERSITY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
